Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL32667175 | 0.98 | L3MBTL1 (0.52) | L3MBTL1PTK2MAP4K1ABL1MAPK8 | |
| SCHEMBL2026558 | 0.86 | L3MBTL1 (0.53) | L3MBTL1PTK2MAP4K1ABL1PIK3C3 | |
| SCHEMBL8328931 | 0.83 | L3MBTL1 (0.59) | L3MBTL1PTK2MAP4K1ABL1PIK3C3 | |
| SCHEMBL18397392 | 0.81 | L3MBTL1 (0.52) | L3MBTL1PTK2MAP4K1ABL1MAPK8 | |
| SCHEMBL32667078 | 0.79 | L3MBTL1 (0.50) | L3MBTL1PTK2MAPK8MAPK9PRKD3 | |
| Hydrochloric Acid SCHEMBL30755858 | 0.79 | L3MBTL1 (0.50) | L3MBTL1PTK2MAPK8MAPK9PRKD3 | |
| Hydrochloric Acid SCHEMBL32667172 | 0.79 | L3MBTL1 (0.46) | L3MBTL1PTK2MAPK8MAPK9PRKD3 | |
| SCHEMBL20861632 | 0.79 | L3MBTL1 (0.53) | L3MBTL1PTK2MAP4K1ABL1PIK3C3 | |
| SCHEMBL20772436 | 0.79 | L3MBTL1 (0.53) | L3MBTL1PTK2MAP4K1ABL1PIK3C3 | |
| SCHEMBL624251 | 0.79 | L3MBTL1 (0.53) | L3MBTL1PTK2MAP4K1ABL1PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2793880-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096630-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096630-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2603216-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012021615-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021615-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | L3MBTL1 196/4885PTK2 2769/4885MAP4K1 1735/4885 |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | L3MBTL1 580/4885PTK2 1187/4885MAP4K1 1307/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | L3MBTL1 866/4885PTK2 2248/4885MAP4K1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.